제테마

216080KOSDAQSector: Pharma & Biotech

₩4,220▼ 3.87%Market cap ₩157.4BAs of Jul 21, 2026 close · updated once daily

Grade D38.7 ptsTop 73% of 2,523 stocks

Financial strength

31.6

Growth momentum

52.1

Price attractiveness

37.2

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

31.6

How much debt does it carry relative to equity?

Debt-to-equity ratio

221.7%

✗ Below median · Top 92.1% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

37.4%

✗ Below median · Top 96.1% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

5.0%

✓ Above median · Top 29.8% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-10.1%

✗ Below median · Top 55.5% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

52.1

How much did revenue grow in a year?

Revenue growth (YoY)

12.2%

✓ Above median · Top 35.8% in sector

Sector median 6.4%

Did core profits grow in a year?

Operating income change (YoY)

-7.1%

✗ Below median · Top 60% in sector

Sector median 3.6%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

37.2

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 60.8% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

2.40x

✗ Below median · Top 64.8% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15